Antibiotic treatment for ocular toxoplasmosis: A systematic review and meta-analysis: Study protocol

Background: Ocular toxoplasmosis (OT) is the most common cause of posterior uveitis, leading to visual impairment in a high proportion of patients. Antibiotics and corticosteroids lower the risk of permanent visual impairment by reducing the size of the retinochoroidal scar, the risk of recurrence, and the severity and duration of acute symptoms. Although OT is a very common cause of infectious posterior uveitis, its treatment remains controversial. Through our systematic review and meta-analysis, we aim to provide the best possible evidence-based information on the safety and effectiveness of the different antibiotic regimes for OT. Methods: This systematic review protocol has been developed based on PRISMA-P guidelines for reporting systematic reviews evaluating health care interventions. We will include all published and unpublished randomized controlled trials (RCTs) comparing different antibiotics used for the treatment of OT. We will consider changes in visual acuity, number of recurrences, improvement or worsening of ocular inflammation, size of lesion, and adverse effects as our outcomes. Screening, data extraction, and quality assessment will be undertaken by two reviewers with disagreements resolved through discussion. Studies that compared antibiotics with placebo will be excluded. The reviews will be assessed for quality and relevance. We will assess the risk of bias in five domains according to Cochrane group's tool. The type of data will dictate measures of treatment effect. We will use a random-effects model to calculate our meta-analysis, as eligible studies represent clinically varied populations of participants. Discussion: The strength of our study will lie in the exhaustive and systematic nature of the literature search, as well as in its methods for assessing quality and analyzing RCT data. Considering the controversial efficacy of the treatment for OT, our study will contribute to improving the existing evidence on the effectiveness of different antibiotics. Future studies may be conducted to increase physicians' awareness of antibiotic therapies, improving the health of patients with OT. Systematic review registration: PROSPERO CRD42018085468. © 2019 The Author(s).

• Fecha de publicación: 2019
• Institución: Universidad del Rosario
• Repositorio: Repositorio EdocUR - U. Rosario
• Idioma: eng
• OAI Identifier: oai:repository.urosario.edu.co:10336/23361
• Acceso en línea: https://doi.org/10.1186/s13643-019-1067-8; https://repository.urosario.edu.co/handle/10336/23361
• Palabra clave: Antibiotic agent; Atovaquone; Azithromycin; Ciprofloxacin; Clarithromycin; Clindamycin; Cotrimoxazole; Dapsone; Doxycycline; Erythromycin; Lincomycin; Macrolide; Methotrexate; Minocycline; Miokamycin; Nifurtimox; Pyrimethamine; Rifabutin; Spiramycin; Sulfadoxine; Sulfafurazole; Sulfamerazine; Sulfonamide; Tetracycline; Blurred vision; Chorioretinitis; Eye inflammation; Genetic heterogeneity; Human; Intraocular pressure; Leukocyte count; Meta analysis; Ocular toxoplasmosis; Optic disk; Outcome assessment; Priority journal; Quality control; Randomized controlled trial (topic); Recurrent disease; Review; Systematic review; Visual acuity; Visual impairment; Anti-bacterial agents; Toxoplasma; Uveitis; ocular; Toxoplasmosis
• License: Abierto (Texto Completo)